Literature DB >> 11682447

Reciprocal regulation of cyclic GMP content by cyclic GMP-phosphodiesterase and guanylate cyclase in SHR with CsA-induced nephrotoxicity.

N Hosogai1, J Seki, T Goto.   

Abstract

1. The effect of the immunosuppressant drug, cyclosporin A (CsA), on the nitric oxide (NO)-cyclic GMP pathway was examined in spontaneous hypertensive rats (SHR). 2. CsA (50 mg kg(-1)) treatment for 14 days induced typical CsA nephrotoxicity, which was characterized by morphological changes in the glomerulus and proximal tubule as well as an abnormality of creatinine clearance, FENa and BUN. 3. CsA significantly decreased both NOS activity in the kidney and NOx contents in urine, but significantly increased cyclic GMP content in the kidney. 4. A marked change in two kinds of enzyme, which contribute towards the increase in cyclic GMP in tissue, namely, a decrease in cyclic GMP-phosphodiesterase activity and increase in guanylate cyclase activity, was observed in the kidney treated with CsA. 5. In the isolated perfused kidney, a decreased in perfusion pressure induced by SNP in the kidney isolated from CsA group was significantly greater than that of control. 6. There seem to exist a reciprocal mechanism to maintain cyclic GMP content via both a decrease in cyclic GMP degradation and an increase in synthesis of cyclic GMP in the kidney treated with CsA. This mechanism is likely to be playing an important role to regulate the homeostasis in the kidney with CsA nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682447      PMCID: PMC1573030          DOI: 10.1038/sj.bjp.0704337

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  L-Arginine and allopurinol protect against cyclosporine nephrotoxicity.

Authors:  S M Assis; J L Monteiro; A C Seguro
Journal:  Transplantation       Date:  1997-04-27       Impact factor: 4.939

2.  Cellular mechanisms of cyclosporine A-associated side-effects: role of endothelin.

Authors:  H Meyer-Lehnert; D Bokemeyer; U Friedrichs; A Bäcker; H J Kramer
Journal:  Kidney Int Suppl       Date:  1997-10       Impact factor: 10.545

3.  Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.

Authors:  S E Thomas; T F Andoh; R H Pichler; S J Shankland; W G Couser; W M Bennett; R J Johnson
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

4.  Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis.

Authors:  A Furusu; M Miyazaki; K Abe; S Tsukasaki; K Shioshita; O Sasaki; K Miyazaki; Y Ozono; T Koji; T Harada; H Sakai; S Kohno
Journal:  Kidney Int       Date:  1998-06       Impact factor: 10.612

Review 5.  Biosynthesis and homeostatic roles of nitric oxide in the normal kidney.

Authors:  B C Kone; C Baylis
Journal:  Am J Physiol       Date:  1997-05

6.  Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression.

Authors:  N A Bobadilla; G Gamba; E Tapia; R García-Torres; A Bolio; P López-Zetina; J Herrera-Acosta
Journal:  Am J Physiol       Date:  1998-04

7.  Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity.

Authors:  T F Andoh; M P Gardner; W M Bennett
Journal:  Transplantation       Date:  1997-11-15       Impact factor: 4.939

8.  Role of endothelin ET(A) receptors in the hypertension produced by 4-day L-nitroarginine methyl ester and cyclosporine treatment.

Authors:  D M Pollock; J S Polakowski; T J Opgenorth; J S Pollock
Journal:  Eur J Pharmacol       Date:  1998-04-03       Impact factor: 4.432

9.  Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity.

Authors:  A Lo Russo; A C Passaquin; P André; M Skutella; U T Rüegg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

10.  Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat.

Authors:  J A Lugg; J Rajfer; N F González-Cadavid
Journal:  Endocrinology       Date:  1995-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.